Fundraising FoxPNP Therapeutics
Birmingham, US · Delaware corporation · 2 known investors
Find your way into PNP Therapeutics
Sign up to see every warm intro you have to PNP Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PNP Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PNP Therapeutics is a clinical-stage biopharmaceutical company developing Gedeptin, a platform technology for cancer treatment that programs tumors to generate their own chemotherapy through a patented enzyme and prodrug system. The company targets patients with solid tumors including prostate, breast, colon, lung, brain, melanoma, pancreas, ovarian, and kidney cancers.
Founders & leadership
WB
William B. Parker, Ph.D.Founder of PNP Therapeutics
EJ
Eric J. Sorscher, M.D.Founding Scientist
WB
William B ParkerNamed on SEC filing
ES
Eric SorscherNamed on SEC filing
Board
CK
Charles K PorterBoard director
CB
Claude BennettBoard director
JL
John LankfordBoard director
LW
Lawrence W GreerBoard director
Investors · 2
Also in the syndicate · 2
Birmingham Technology FundPhase 1 Holdings, LLC
Funding
SEC filings, press & company announcements$853.9K disclosed across 3 of 4 rounds · 2007–2018
- Undisclosed amountSeries BJun 2007
Birmingham Technology Fund, Phase 1 Holdings, LLC
Source ↗
▶$123.9KraisedAug 2018 · 9 investors · BiotechnologyRule 506(b)
▶$123.9KraisedAug 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence W GreerDirector
- Claude BennettDirector
- William B ParkerExecutive Officer, Director
- Charles K PorterDirector
- James F FuquaExecutive Officer, Director
- Eric SorscherDirector
- John LankfordDirector
- Offering amount
- $768K
- Amount sold
- $123.9K
- Minimum investment
- $1.5K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$336KraisedJun 2016 · 14 investors · BiotechnologyRule 506(b)
▶$336KraisedJun 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William B ParkerExecutive Officer, Director
- James F FuquaExecutive Officer, Director
- Charles K PorterDirector
- Claude BennettDirector
- John LankfordDirector
- Eric SorscherDirector
- Lawrence W GreerDirector
- Offering amount
- $336K
- Amount sold
- $336K
- Minimum investment
- $10K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$394KraisedOct 2014 · 10 investors · BiotechnologyRule 506(b)
▶$394KraisedOct 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence W GreerDirector
- John LankfordDirector
- William B ParkerExecutive Officer, Director
- Claude BennettDirector
- James F FuquaExecutive Officer, Director
- Charles K PorterDirector
- Offering amount
- $394K
- Amount sold
- $394K
- Minimum investment
- $10K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
PDX PharmaceuticalsPDX Pharmaceuticals develops mesoporous silica nanoparticle platforms to co-deliver drugs, siRNA, and immunotherapy for treating multiple cancers and skin diseases. The company works in collaboration with OHSU on targeted and combination immunotherapeutics.
PhanestheraPhanes Therapeutics develops oncology and metabolic disease therapeutics targeting cell cycle regulators and related pathways. The company operates from San Diego with operations including a research site in Shanghai.
Bridge TherapeuticsBridge Therapeutics is a development-stage pharmaceutical company developing BT-219 (Bunalz), a buprenorphine/naloxone orally disintegrating tablet for Opioid Use Disorder, and BT-205, a buprenorphine/meloxicam sublingual combination for chronic pain in opioid-experienced patients. Both drug candidates are being pursued through the FDA 505(B)(2) approval pathway.
SeamlessSeamless is a revenue operations platform that uses AI to automate sales outreach and contact verification for sales, marketing, and customer success teams. It identifies target buyers, verifies contact information in real time, and orchestrates multi-channel outreach via email, phone, and social media to generate meetings and pipeline.
Companies working in the same space as PNP Therapeutics.
In the news
Frequently asked questions
- What does PNP Therapeutics do?
- PNP Therapeutics is a clinical-stage biopharmaceutical company developing Gedeptin, a platform technology for cancer treatment that programs tumors to generate their own chemotherapy through a patented enzyme and prodrug system. The company targets patients with solid tumors including prostate, breast, colon, lung, brain, melanoma, pancreas, ovarian, and kidney cancers.
- Who founded PNP Therapeutics?
- PNP Therapeutics was founded by William B. Parker, Ph.D., Eric J. Sorscher, M.D..
- How much funding has PNP Therapeutics raised?
- PNP Therapeutics has disclosed $853.9K raised across 3 of its 4 known rounds.
- Where is PNP Therapeutics headquartered?
- PNP Therapeutics is headquartered in Birmingham, US.